353 related articles for article (PubMed ID: 24257962)
21. A dose-optimization trial of laronidase (Aldurazyme) in patients with mucopolysaccharidosis I.
Giugliani R; Rojas VM; Martins AM; Valadares ER; Clarke JT; Góes JE; Kakkis ED; Worden MA; Sidman M; Cox GF
Mol Genet Metab; 2009 Jan; 96(1):13-9. PubMed ID: 19038563
[TBL] [Abstract][Full Text] [Related]
22. Laronidase treatment of mucopolysaccharidosis I.
Wraith EJ; Hopwood JJ; Fuller M; Meikle PJ; Brooks DA
BioDrugs; 2005; 19(1):1-7. PubMed ID: 15691212
[TBL] [Abstract][Full Text] [Related]
23. Enzyme replacement therapy for infantile-onset Pompe disease.
Chen M; Zhang L; Quan S
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011539. PubMed ID: 29155436
[TBL] [Abstract][Full Text] [Related]
24. Enzyme replacement therapy in mucopolysaccharidosis type I.
Miebach E
Acta Paediatr Suppl; 2005 Mar; 94(447):58-60; discussion 57. PubMed ID: 15895714
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of intravenous laronidase for mucopolysaccharidosis type I: A systematic review and meta-analysis.
Dornelles AD; Artigalás O; da Silva AA; Ardila DLV; Alegra T; Pereira TV; Vairo FPE; Schwartz IVD
PLoS One; 2017; 12(8):e0184065. PubMed ID: 28859139
[TBL] [Abstract][Full Text] [Related]
26. The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis.
Dualibi AP; Martins AM; Moreira GA; de Azevedo MF; Fujita RR; Pignatari SS
Braz J Otorhinolaryngol; 2016; 82(5):522-8. PubMed ID: 26750310
[TBL] [Abstract][Full Text] [Related]
27. 18-year follow-up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I.
Pjetraj D; Santoro L; Sgattoni C; Padella L; Zampini L; Monachesi C; Gabrielli O; Catassi C
Am J Med Genet A; 2023 Feb; 191(2):564-569. PubMed ID: 36333985
[TBL] [Abstract][Full Text] [Related]
28. Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS).
Spataro F; Viggiani F; Macchia DG; Rollo V; Tummolo A; Suppressa P; Sabba' C; Rossi MP; Giliberti L; Satriano F; Nettis E; Di Bona D; Caiaffa MF; Fischetto R; Macchia L
Orphanet J Rare Dis; 2022 Nov; 17(1):402. PubMed ID: 36329518
[TBL] [Abstract][Full Text] [Related]
29. Open issues in Mucopolysaccharidosis type I-Hurler.
Parini R; Deodato F; Di Rocco M; Lanino E; Locatelli F; Messina C; Rovelli A; Scarpa M
Orphanet J Rare Dis; 2017 Jun; 12(1):112. PubMed ID: 28619065
[TBL] [Abstract][Full Text] [Related]
30. Successful pregnancy and breastfeeding in a woman with mucopolysaccharidosis type I while receiving laronidase enzyme replacement. therapy.
Castorina M; Antuzzi D; Richards SM; Cox GF; Xue Y
Clin Exp Obstet Gynecol; 2015; 42(1):108-13. PubMed ID: 25864295
[TBL] [Abstract][Full Text] [Related]
31. Enzyme replacement therapy for Anderson-Fabry disease.
El Dib R; Gomaa H; Carvalho RP; Camargo SE; Bazan R; Barretti P; Barreto FC
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD006663. PubMed ID: 27454104
[TBL] [Abstract][Full Text] [Related]
32. Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
[TBL] [Abstract][Full Text] [Related]
33. Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I.
Dickson PI; Kaitila I; Harmatz P; Mlikotic A; Chen AH; Victoroff A; Passage MB; Madden J; Le SQ; Naylor DE;
Mol Genet Metab; 2015; 116(1-2):69-74. PubMed ID: 26260077
[TBL] [Abstract][Full Text] [Related]
34. Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler-Scheie patient.
Soutar RL; Mercer J; Wraith JE
J Inherit Metab Dis; 2006 Aug; 29(4):590. PubMed ID: 16830264
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of laronidase therapy in patients with mucopolysaccharidosis type I who initiated enzyme replacement therapy in adult age. A systematic review and meta-analysis.
Pérez-López J; Morales-Conejo M; López-Rodríguez M; Hermida-Ameijeiras Á; Moltó-Abad M
Mol Genet Metab; 2017 Jun; 121(2):138-149. PubMed ID: 28410878
[TBL] [Abstract][Full Text] [Related]
36. Intrathecal enzyme replacement for cognitive decline in mucopolysaccharidosis type I, a randomized, open-label, controlled pilot study.
Chen AH; Harmatz P; Nestrasil I; Eisengart JB; King KE; Rudser K; Kaizer AM; Svatkova A; Wakumoto A; Le SQ; Madden J; Young S; Zhang H; Polgreen LE; Dickson PI
Mol Genet Metab; 2020 Feb; 129(2):80-90. PubMed ID: 31839529
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of recombinant human alpha-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients.
Tylki-Szymanska A; Marucha J; Jurecka A; Syczewska M; Czartoryska B
J Inherit Metab Dis; 2010 Apr; 33(2):151-7. PubMed ID: 20217237
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of a Combination Therapy with Laronidase and Genistein in Treating Mucopolysaccharidosis Type I in a Mouse Model.
Malinowska M; Nowicka W; Kloska A; Węgrzyn G; Jakóbkiewicz-Banecka J
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397051
[TBL] [Abstract][Full Text] [Related]
39. The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I.
Wraith JE
Expert Opin Pharmacother; 2005 Mar; 6(3):489-506. PubMed ID: 15794739
[TBL] [Abstract][Full Text] [Related]
40. [The development of cognitive functions in children with Hurler phenotype mucopolysaccharidosis type I on enzyme replacement therapy with laronidase].
Biernacka M; Jakubowska-Winecka A; Tylki-Szymańska A
Pediatr Endocrinol Diabetes Metab; 2010; 16(4):249-54. PubMed ID: 21447265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
